This Oxfordshire firm, led by chief executive Eliot Forster, 49, develops drugs that harness the body’s immune system to fight cancer — in early trials its products have shown promising results against advanced melanoma. In July it completed the largest financing for a private life sciences company in Europe so far, raising £205m from investors including Eli Lilly and Malin. The company’s revenue, from partnerships with large pharmaceutical companies such as Glaxo Smith Kline and Astra Zeneca, reached £6.4m in 2014, when it made a big loss.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.